Market
What will be the outcome of the VA MDMA study by end of 2029?
2
Resolution / Starting Odds
Significant positive results • 25%
Moderate positive results • 25%
No significant results • 25%
Negative results • 25%
Study results published in academic journals or official reports from Brown University, Yale University, or the VA
Story
VA Funds $1.5 Million Study on MDMA-Assisted Therapy for Veterans with PTSD, First Psychedelic Research Since 1960s
Dec 5, 2024, 04:04 PM
The U.S. Department of Veterans Affairs (VA) has announced a historic initiative to fund a $1.5 million study on MDMA-assisted therapy aimed at treating post-traumatic stress disorder (PTSD) and alcohol use disorder among veterans. This marks the VA's first support for psychedelic research since the 1960s. Representatives Jack Bergman (R-MI) and Lou Correa (D-CA) have expressed their support for the initiative, highlighting its potential to address the veteran suicide crisis, which is reported to be 57% higher than that of civilians. The five-year study will be conducted by researchers from Brown University and Yale University. The decision to explore MDMA as a therapeutic option reflects a growing interest in psychedelics for mental health treatment, particularly in light of recent studies indicating their efficacy in reducing symptoms of PTSD and depression.
View original story
Similar markets
Effective for both PTSD and alcohol use disorder • 25%
Not effective for either condition • 25%
Effective only for alcohol use disorder • 25%
Effective only for PTSD • 25%
Moderate positive impact • 25%
Negative impact • 25%
No significant impact • 25%
Significant positive impact • 25%
Widely positive • 25%
Mixed • 25%
Mostly negative • 25%
Indifferent • 25%
Decreased funding • 25%
Increased funding • 25%
Same level of funding • 25%
No funding • 25%
Yes • 50%
No • 50%
Successful trial • 33%
Unsuccessful trial • 33%
Inconclusive results • 34%
Moderate improvement • 25%
Significant improvement • 25%
No improvement • 25%
Worsening condition • 25%
Study inconclusive • 25%
Negative immunogenicity results • 25%
Negative safety results • 25%
Positive safety and immunogenicity results • 25%